Envafolimab and Chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer (B-Enefits/SCOG-B001): A single-arm, exploratory, phase 2 trial

ABSTRACT: BTC represents a rare malignancy with unfavorable prognosis. Here we conducted a single-arm, multicenter, prospective phase Ⅱclinical study (ChiCTR2400080783) to evaluate the efficacy and safety of envafolimab and chidamide in combination with gemcitabine plus oxaliplatin (GEMOX) as first-line treatment. 10×scRNA-seq was adopted to conduct an initial exploration into the potential mechanisms underlying the efficacy of the combination regimen.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE301188 | GEO | 2025/07/31

REPOSITORIES: GEO